Cargando…

Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma

Mantle cell lymphoma (MCL) is an incurable B cell non-Hodgkin lymphoma, characterized by frequent relapses. In the last decade, the pro-survival pathways related to BCR signaling and Bcl-2 have been considered rational therapeutic targets in B cell derived lymphomas. The BTK inhibitor Ibrutinib and...

Descripción completa

Detalles Bibliográficos
Autores principales: Manni, Sabrina, Pesavento, Maria, Spinello, Zaira, Saggin, Lara, Arjomand, Arash, Fregnani, Anna, Quotti Tubi, Laura, Scapinello, Greta, Gurrieri, Carmela, Semenzato, Gianpietro, Trentin, Livio, Piazza, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403710/
https://www.ncbi.nlm.nih.gov/pubmed/36035991
http://dx.doi.org/10.3389/fcell.2022.935023
_version_ 1784773440060784640
author Manni, Sabrina
Pesavento, Maria
Spinello, Zaira
Saggin, Lara
Arjomand, Arash
Fregnani, Anna
Quotti Tubi, Laura
Scapinello, Greta
Gurrieri, Carmela
Semenzato, Gianpietro
Trentin, Livio
Piazza, Francesco
author_facet Manni, Sabrina
Pesavento, Maria
Spinello, Zaira
Saggin, Lara
Arjomand, Arash
Fregnani, Anna
Quotti Tubi, Laura
Scapinello, Greta
Gurrieri, Carmela
Semenzato, Gianpietro
Trentin, Livio
Piazza, Francesco
author_sort Manni, Sabrina
collection PubMed
description Mantle cell lymphoma (MCL) is an incurable B cell non-Hodgkin lymphoma, characterized by frequent relapses. In the last decade, the pro-survival pathways related to BCR signaling and Bcl-2 have been considered rational therapeutic targets in B cell derived lymphomas. The BTK inhibitor Ibrutinib and the Bcl-2 inhibitor Venetoclax are emerging as effective drugs for MCL. However, primary and acquired resistance also to these agents may occur. Protein Kinase CK2 is a S/T kinase overexpressed in many solid and blood-derived tumours. CK2 promotes cancer cell growth and clonal expansion, sustaining pivotal survival signaling cascades, such as the ones dependent on AKT, NF-κB, STAT3 and others, counteracting apoptosis through a “non-oncogene” addiction mechanism. We previously showed that CK2 is overexpressed in MCL and regulates the levels of activating phosphorylation on S529 of the NF-κB family member p65/RelA. In the present study, we investigated the effects of CK2 inactivation on MCL cell proliferation, survival and apoptosis and this kinase’s involvement in the BCR and Bcl-2 related signaling. By employing CK2 loss of function MCL cell models, we demonstrated that CK2 sustains BCR signaling (such as BTK, NF-κB and AKT) and the Bcl-2-related Mcl-1 expression. CK2 inactivation enhanced Ibrutinib and Venetoclax-induced cytotoxicity. The demonstration of a CK2-dependent upregulation of pathways that may antagonize the effect of these drugs may offer a novel strategy to overcome primary and secondary resistance.
format Online
Article
Text
id pubmed-9403710
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94037102022-08-26 Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma Manni, Sabrina Pesavento, Maria Spinello, Zaira Saggin, Lara Arjomand, Arash Fregnani, Anna Quotti Tubi, Laura Scapinello, Greta Gurrieri, Carmela Semenzato, Gianpietro Trentin, Livio Piazza, Francesco Front Cell Dev Biol Cell and Developmental Biology Mantle cell lymphoma (MCL) is an incurable B cell non-Hodgkin lymphoma, characterized by frequent relapses. In the last decade, the pro-survival pathways related to BCR signaling and Bcl-2 have been considered rational therapeutic targets in B cell derived lymphomas. The BTK inhibitor Ibrutinib and the Bcl-2 inhibitor Venetoclax are emerging as effective drugs for MCL. However, primary and acquired resistance also to these agents may occur. Protein Kinase CK2 is a S/T kinase overexpressed in many solid and blood-derived tumours. CK2 promotes cancer cell growth and clonal expansion, sustaining pivotal survival signaling cascades, such as the ones dependent on AKT, NF-κB, STAT3 and others, counteracting apoptosis through a “non-oncogene” addiction mechanism. We previously showed that CK2 is overexpressed in MCL and regulates the levels of activating phosphorylation on S529 of the NF-κB family member p65/RelA. In the present study, we investigated the effects of CK2 inactivation on MCL cell proliferation, survival and apoptosis and this kinase’s involvement in the BCR and Bcl-2 related signaling. By employing CK2 loss of function MCL cell models, we demonstrated that CK2 sustains BCR signaling (such as BTK, NF-κB and AKT) and the Bcl-2-related Mcl-1 expression. CK2 inactivation enhanced Ibrutinib and Venetoclax-induced cytotoxicity. The demonstration of a CK2-dependent upregulation of pathways that may antagonize the effect of these drugs may offer a novel strategy to overcome primary and secondary resistance. Frontiers Media S.A. 2022-08-11 /pmc/articles/PMC9403710/ /pubmed/36035991 http://dx.doi.org/10.3389/fcell.2022.935023 Text en Copyright © 2022 Manni, Pesavento, Spinello, Saggin, Arjomand, Fregnani, Quotti Tubi, Scapinello, Gurrieri, Semenzato, Trentin and Piazza. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Manni, Sabrina
Pesavento, Maria
Spinello, Zaira
Saggin, Lara
Arjomand, Arash
Fregnani, Anna
Quotti Tubi, Laura
Scapinello, Greta
Gurrieri, Carmela
Semenzato, Gianpietro
Trentin, Livio
Piazza, Francesco
Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma
title Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma
title_full Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma
title_fullStr Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma
title_full_unstemmed Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma
title_short Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma
title_sort protein kinase ck2 represents a new target to boost ibrutinib and venetoclax induced cytotoxicity in mantle cell lymphoma
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403710/
https://www.ncbi.nlm.nih.gov/pubmed/36035991
http://dx.doi.org/10.3389/fcell.2022.935023
work_keys_str_mv AT mannisabrina proteinkinaseck2representsanewtargettoboostibrutinibandvenetoclaxinducedcytotoxicityinmantlecelllymphoma
AT pesaventomaria proteinkinaseck2representsanewtargettoboostibrutinibandvenetoclaxinducedcytotoxicityinmantlecelllymphoma
AT spinellozaira proteinkinaseck2representsanewtargettoboostibrutinibandvenetoclaxinducedcytotoxicityinmantlecelllymphoma
AT sagginlara proteinkinaseck2representsanewtargettoboostibrutinibandvenetoclaxinducedcytotoxicityinmantlecelllymphoma
AT arjomandarash proteinkinaseck2representsanewtargettoboostibrutinibandvenetoclaxinducedcytotoxicityinmantlecelllymphoma
AT fregnanianna proteinkinaseck2representsanewtargettoboostibrutinibandvenetoclaxinducedcytotoxicityinmantlecelllymphoma
AT quottitubilaura proteinkinaseck2representsanewtargettoboostibrutinibandvenetoclaxinducedcytotoxicityinmantlecelllymphoma
AT scapinellogreta proteinkinaseck2representsanewtargettoboostibrutinibandvenetoclaxinducedcytotoxicityinmantlecelllymphoma
AT gurriericarmela proteinkinaseck2representsanewtargettoboostibrutinibandvenetoclaxinducedcytotoxicityinmantlecelllymphoma
AT semenzatogianpietro proteinkinaseck2representsanewtargettoboostibrutinibandvenetoclaxinducedcytotoxicityinmantlecelllymphoma
AT trentinlivio proteinkinaseck2representsanewtargettoboostibrutinibandvenetoclaxinducedcytotoxicityinmantlecelllymphoma
AT piazzafrancesco proteinkinaseck2representsanewtargettoboostibrutinibandvenetoclaxinducedcytotoxicityinmantlecelllymphoma